{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:02:56Z","timestamp":1787320976784,"version":"build-2736575974"},"reference-count":73,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Statins and ezetimibe are widely used and safe lipid-lowering therapies for the prevention of atherosclerotic cardiovascular disease. However, concerns persist, especially among the lay public, about the possibility of a long-term association with cancer incidence and cancer-related mortality. To evaluate the association between statin therapy, statin intensity, ezetimibe, and statin\u2013ezetimibe combination therapy with cancer incidence and cancer-related mortality using a network meta-analysis of randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a systematic review and Bayesian network meta-analysis of randomized controlled trials comparing statin monotherapy, statin\u2013ezetimibe combination, or ezetimibe monotherapy with no lipid-lowering therapy (no-LLT), including head-to-head comparisons of statin intensities. PubMed\/MEDLINE, Embase, and Cochrane were searched through February 2026. Treatment effects were estimated using random-effects Bayesian models and expressed as risk ratios (RRs) with 95% credible intervals (CrIs). A total of 69 randomized controlled trials, including 238 533 participants, were analysed, of whom 199 286 received statins, 35 836 received statins plus ezetimibe, and 3411 received ezetimibe alone. For cancer incidence, high-intensity statins (RR 0.95, 95% CrI 0.87\u20131.03), moderate-intensity statins (RR 1.01, 95% CrI 0.96\u20131.05), low-intensity statins (RR 1.06, 95% CrI 0.72\u20131.61), and moderate-intensity statin plus ezetimibe (RR 1.04, 95% CrI 0.96\u20131.14) were not associated with a reduction compared with no-LLT. For cancer mortality, no significant differences were observed with high-intensity statins (RR 0.94, 95% CrI 0.79\u20131.09), moderate-intensity statins (RR 1.00, 95% CrI 0.92\u20131.08), low-intensity statins (RR 1.70, 95% CrI 0.50\u20136.06), moderate-intensity statin plus ezetimibe (RR 1.12, 95% CrI 0.97\u20131.32), or ezetimibe alone (RR 1.32, 95% CrI 0.82\u20132.15), all compared with no-LLT. All head-to-head comparisons among active treatment nodes (statin intensities, statin\u2013ezetimibe combination, and ezetimibe monotherapy) were similarly null, with point estimates close to unity and 95% CrIs crossing 1.0 for all comparisons. Node-splitting revealed no significant inconsistency between direct and indirect evidence for any evaluable comparison. Subtype analyses for lung, breast, gastrointestinal, genitourinary, haematological, skin, and central nervous system cancers showed no significant differences across treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this network meta-analysis of randomized trials, statin therapy across all intensities and ezetimibe, alone or in combination, was not associated with an increased risk of cancer incidence or cancer-related mortality, supporting their oncologic safety within the duration of follow-up available in randomized clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag392","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T11:32:43Z","timestamp":1785065563000},"source":"Crossref","is-referenced-by-count":0,"title":["Association of cancer incidence and cancer-related mortality with statin therapy, ezetimibe, and statin\u2013ezetimibe combination: a systematic review and Bayesian network meta-analysis of randomized controlled trials"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1145-9752","authenticated-orcid":false,"given":"Natasha","family":"Ghalib","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, University of Louisville School of Medicine , 201 Abraham Flexner Way, Suite 600, Louisville, KY 40202 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahima","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, University of Louisville School of Medicine , 201 Abraham Flexner Way, Suite 600, Louisville, KY 40202 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Virani","sequence":"additional","affiliation":[{"name":"The Aga Khan University , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5147-5469","authenticated-orcid":false,"given":"Kevin","family":"Maki","sequence":"additional","affiliation":[{"name":"Midwest Biomedical Research , Addison, IL ,","place":["USA"]},{"name":"Department of Applied Health Science, Indiana University School of Public Health , Bloomington, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-6370","authenticated-orcid":false,"given":"Laurence","family":"Sperling","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Emory University School of Medicine , Atlanta, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[{"name":"Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL) , Lodz ,","place":["Poland"]},{"name":"Faculty of Medicine, The John Paul II Catholic University of Lublin , Lublin ,","place":["Poland"]},{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nanna","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Barton","family":"Duell","sequence":"additional","affiliation":[{"name":"Knight Cardiovascular Institute and Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University , Portland, OR ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Public Health, School of Public Health, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Center for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Wake Forest University School of Medicine , Winston-Salem, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-9818","authenticated-orcid":false,"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Princess Grace Hospital , Centre Hospitalier Princesse Grace, 1 avenue Pasteur, BP 489, MC 980 12 CEDEX, Monaco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-4067","authenticated-orcid":false,"given":"Dinesh K","family":"Kalra","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, University of Louisville School of Medicine , 201 Abraham Flexner Way, Suite 600, Louisville, KY 40202 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2026082109014388100_zwag392-B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"2026082109014388100_zwag392-B2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"2026082109014388100_zwag392-B3","first-page":"559","article-title":"A look to the past - what has had the biggest impact on lipids in the last four decades? A personal perspective","volume":"19","author":"Banach","year":"2023","journal-title":"Arch Med Sci"},{"key":"2026082109014388100_zwag392-B4","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"2026082109014388100_zwag392-B5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrd1112","article-title":"Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors","volume":"2","author":"Tobert","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2026082109014388100_zwag392-B6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MOL.0b013e32834c7c28","article-title":"Intestinal sterol transporters and cholesterol absorption inhibition","volume":"22","author":"Davis","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"2026082109014388100_zwag392-B7","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026082109014388100_zwag392-B8","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s40265-024-02105-5","article-title":"2024 recommendations on the optimal use of lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: a position paper of the International Lipid Expert Panel (ILEP)","volume":"84","author":"Banach","year":"2024","journal-title":"Drugs"},{"key":"2026082109014388100_zwag392-B9","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.CIR.86.3.1046","article-title":"Report of the conference on low blood cholesterol: mortality associations","volume":"86","author":"Jacobs","year":"1992","journal-title":"Circulation"},{"key":"2026082109014388100_zwag392-B10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/bmj.311.7002.409","article-title":"Low serum total cholesterol concentrations and mortality in middle aged British men","volume":"311","author":"Wannamethee","year":"1995","journal-title":"BMJ"},{"key":"2026082109014388100_zwag392-B11","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1158\/1055-9965.EPI-08-1248","article-title":"Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer","volume":"18","author":"Ahn","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026082109014388100_zwag392-B12","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/annonc\/mdn736","article-title":"Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172210 men and women: a prospective 19-year follow-up study","volume":"20","author":"Strasak","year":"2009","journal-title":"Ann Oncol"},{"key":"2026082109014388100_zwag392-B13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41580-019-0190-7","article-title":"Mechanisms and regulation of cholesterol homeostasis","volume":"21","author":"Luo","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026082109014388100_zwag392-B14","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1158\/0008-5472.CAN-15-2613","article-title":"The role of cholesterol in cancer","volume":"76","author":"Kuzu","year":"2016","journal-title":"Cancer Res"},{"key":"2026082109014388100_zwag392-B15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.11-3-306","article-title":"The role of statins in cancer therapy","volume":"11","author":"Hindler","year":"2006","journal-title":"Oncologist"},{"key":"2026082109014388100_zwag392-B16","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.1200\/JCO.2005.02.7045","article-title":"Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies","volume":"23","author":"Bonovas","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026082109014388100_zwag392-B17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrclinonc.2013.169","article-title":"Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates","volume":"10","author":"Gronich","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"2026082109014388100_zwag392-B18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13046-021-02041-2","article-title":"Statins: a repurposed drug to fight cancer","volume":"40","author":"Jiang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026082109014388100_zwag392-B19","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2217\/fon-2017-0543","article-title":"Statins use and cancer: an update","volume":"14","author":"Zaleska","year":"2018","journal-title":"Future Oncol"},{"key":"2026082109014388100_zwag392-B20","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"2026082109014388100_zwag392-B21","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","journal-title":"N Engl J Med"},{"key":"2026082109014388100_zwag392-B22","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"2026082109014388100_zwag392-B23","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"2026082109014388100_zwag392-B24","doi-asserted-by":"crossref","first-page":"831657","DOI":"10.3389\/fphar.2022.831657","article-title":"Ezetimibe and cancer: is there a connection?","volume":"13","author":"Gu","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026082109014388100_zwag392-B25","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N Engl J Med"},{"key":"2026082109014388100_zwag392-B26","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2026082109014388100_zwag392-B27","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12944-023-01955-4","article-title":"The association of statin therapy and cancer: a meta-analysis","volume":"22","author":"Chen","year":"2023","journal-title":"Lipids Health Dis"},{"key":"2026082109014388100_zwag392-B28","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.ejca.2008.06.025","article-title":"Statins and cancer: a systematic review and meta-analysis","volume":"44","author":"Kuoppala","year":"2008","journal-title":"Eur J Cancer"},{"key":"2026082109014388100_zwag392-B29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.295.1.74","article-title":"Statins and cancer risk: a meta-analysis","volume":"295","author":"Dale","year":"2006","journal-title":"JAMA"},{"key":"2026082109014388100_zwag392-B30","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions.","author":"Higgins"},{"key":"2026082109014388100_zwag392-B31","doi-asserted-by":"crossref","first-page":"111537","DOI":"10.1016\/j.jclinepi.2024.111537","article-title":"Network meta-analysis: a powerful tool for clinicians, decision-makers, and methodologists","volume":"176","author":"Florez","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"2026082109014388100_zwag392-B32","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1136\/archdischild-2018-315224","article-title":"Network meta-analysis explained","volume":"104","author":"Dias","year":"2019","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"2026082109014388100_zwag392-B33","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026082109014388100_zwag392-B34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2026082109014388100_zwag392-B35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s42256-020-00287-7","article-title":"An open source machine learning framework for efficient and transparent systematic reviews","volume":"3","author":"Van De Schoot","year":"2021","journal-title":"Nat Mach Intell"},{"key":"2026082109014388100_zwag392-B36","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst Rev"},{"key":"2026082109014388100_zwag392-B37","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2026082109014388100_zwag392-B38","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026082109014388100_zwag392-B39","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1017\/S1466252319000343","article-title":"How to read and interpret the results of a Bayesian network meta-analysis: a short tutorial","volume":"20","author":"Hu","year":"2019","journal-title":"Anim Health Res Rev"},{"key":"2026082109014388100_zwag392-B40","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/jrsm.1475","article-title":"On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis","volume":"12","author":"R\u00f6ver","year":"2021","journal-title":"Res Synth Methods"},{"key":"2026082109014388100_zwag392-B41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1214\/ss\/1177011136","article-title":"Inference from iterative simulation using multiple sequences","volume":"7","author":"Gelman","year":"1992","journal-title":"Statist Sci"},{"key":"2026082109014388100_zwag392-B42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1198\/016214505000001302","article-title":"Assessing evidence inconsistency in mixed treatment comparisons","volume":"101","author":"Lu","year":"2006","journal-title":"J Am Stat Assoc"},{"key":"2026082109014388100_zwag392-B43","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"2026082109014388100_zwag392-B44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmjebm-2020-111603","article-title":"Bayesian interpretation of p values in clinical trials","volume":"27","author":"Ferguson","year":"2022","journal-title":"BMJ Evid Based Med"},{"key":"2026082109014388100_zwag392-B45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2026082109014388100_zwag392-B46","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"2026082109014388100_zwag392-B47","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2026082109014388100_zwag392-B48","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/j.jval.2024.10.2339","article-title":"MSR105 tackling rare events in network meta-analysis: comparative performance of methods for sparse safety outcomes","volume":"27","author":"Friedrich","year":"2024","journal-title":"Value Health"},{"key":"2026082109014388100_zwag392-B49","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1002\/sim.9562","article-title":"Network meta-analysis of rare events using penalized likelihood regression","volume":"41","author":"Evrenoglou","year":"2022","journal-title":"Stat Med"},{"key":"2026082109014388100_zwag392-B50","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"key":"2026082109014388100_zwag392-B51","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jrsm.1370","article-title":"Random-effects meta-analysis of few studies involving rare events","volume":"11","author":"G\u00fcnhan","year":"2020","journal-title":"Res Synth Methods"},{"key":"2026082109014388100_zwag392-B52","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"key":"2026082109014388100_zwag392-B53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"2026082109014388100_zwag392-B54","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12916-021-02166-3","article-title":"ROB-MEN: a tool to assess risk of bias due to missing evidence in network meta-analysis","volume":"19","author":"Chiocchia","year":"2021","journal-title":"BMC Med"},{"key":"2026082109014388100_zwag392-B55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12874-023-02038-9","article-title":"Semi-automated assessment of the risk of bias due to missing evidence in network meta-analysis: a guidance paper for the ROB-MEN web-application","volume":"23","author":"Chiocchia","year":"2023","journal-title":"BMC Med Res Methodol"},{"key":"2026082109014388100_zwag392-B56","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-075837","article-title":"Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial","volume":"383","author":"Lee","year":"2023","journal-title":"BMJ"},{"key":"2026082109014388100_zwag392-B57","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"2026082109014388100_zwag392-B58","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(25)01578-8","article-title":"Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials","volume":"407","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2026","journal-title":"Lancet"},{"key":"2026082109014388100_zwag392-B59","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026082109014388100_zwag392-B60","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/MOL.0b013e328010872d","article-title":"The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy","volume":"17","author":"Wiviott","year":"2006","journal-title":"Curr Opin Lipidol"},{"key":"2026082109014388100_zwag392-B61","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.amjcard.2014.08.041","article-title":"Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (&lt;30 mg\/dL) with rosuvastatin 20\u2005mg daily (from JUPITER)","volume":"114","author":"Everett","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026082109014388100_zwag392-B62","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1200\/JCO.2004.02.027","article-title":"The risk of cancer in users of statins","volume":"22","author":"Graaf","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026082109014388100_zwag392-B63","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","article-title":"Statins and the risk of colorectal cancer","volume":"352","author":"Poynter","year":"2005","journal-title":"N Engl J Med"},{"key":"2026082109014388100_zwag392-B64","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N Engl J Med"},{"key":"2026082109014388100_zwag392-B65","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026082109014388100_zwag392-B66","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026082109014388100_zwag392-B67","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ijc.22366","article-title":"Statins and risk of cancer: a systematic review and metaanalysis","volume":"120","author":"Browning","year":"2007","journal-title":"Int J Cancer"},{"key":"2026082109014388100_zwag392-B68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.annepidem.2023.05.004","article-title":"The application of lag times in cancer pharmacoepidemiology: a narrative review","volume":"84","author":"Hicks","year":"2023","journal-title":"Ann Epidemiol"},{"key":"2026082109014388100_zwag392-B69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/746769","article-title":"Estimating cancer latency times using a Weibull model","volume":"2014","author":"Nadler","year":"2014","journal-title":"Adv Epidemiol"},{"key":"2026082109014388100_zwag392-B70","author":"Howard"},{"key":"2026082109014388100_zwag392-B71","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/nature09515","article-title":"Distant metastasis occurs late during the genetic evolution of pancreatic cancer","volume":"467","author":"Yachida","year":"2010","journal-title":"Nature"},{"key":"2026082109014388100_zwag392-B72","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/jnci\/djr008","article-title":"Low-density lipoprotein cholesterol and the risk of cancer: a Mendelian randomization study","volume":"103","author":"Benn","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2026082109014388100_zwag392-B73","first-page":"1602","article-title":"2023: the year in cardiovascular disease\u2014the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?","volume":"19","author":"Banach","year":"2023","journal-title":"Arch Med Sci"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag392\/70299383\/zwag392.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag392\/70299383\/zwag392.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:02:01Z","timestamp":1787317321000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag392\/8746390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":73,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag392","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"zwag392"}}